← The Wire
EXELNasdaq
EXELIXIS, INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 939767
Exelixis innovates and develops next-generation oncology medicines and regimens for cancer care
red 8-K · 90d
$13.35B
Market cap
$54.28
Last close
-0.9%
1D
+5.7%
5D
2.6M
Volume
Price · last 39 sessions+22.9%
May 4L $44.17 · H $54.77Jun 29
159
Total filings
May 29, 2026
Last filing
01/01
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 29, 202610-Q10-QMay 5, 20268-KResults of Operations · Company UpdateMay 5, 2026DEFA14ADEFA14AApr 17, 2026DEFA14ADEFA14AApr 15, 2026DEF 14ADEFA14AApr 15, 202610-K10-KFeb 10, 20268-KResults of OperationsFeb 10, 20268-KResults of OperationsJan 12, 2026SC 13D/ASC 13D/AJan 5, 20268-KExecutive Change · Company UpdateNov 7, 202510-Q10-QNov 4, 20258-KResults of Operations · Company UpdateNov 4, 20258-KExecutive ChangeAug 29, 202510-Q10-QJul 28, 20258-KResults of OperationsJul 28, 20258-KShareholder VoteJun 2, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEFA14ADEFA14AApr 16, 2025DEF 14ADEF 14AApr 16, 20258-KExecutive ChangeMar 31, 20258-KCompany UpdateFeb 21, 202510-K10-KFeb 11, 20258-KResults of OperationsFeb 11, 20258-KResults of OperationsJan 13, 202510-Q10-QOct 29, 20248-KResults of OperationsOct 29, 20248-KCompany UpdateOct 15, 20248-KCompany UpdateOct 15, 202410-Q10-QAug 6, 20248-KResults of Operations · Company UpdateAug 6, 20248-KExecutive Change · Shareholder VoteJun 3, 20248-KCompany UpdateMay 20, 20248-KCompany UpdateMay 10, 202410-Q10-QApr 30, 20248-KResults of OperationsApr 30, 2024DEFA14ADEFA14AApr 18, 2024DEF 14ADEF 14AApr 18, 20248-KExecutive ChangeMar 29, 2024SC 13GSC 13GFeb 13, 202410-K10-KFeb 6, 20248-KResults of OperationsFeb 6, 20248-KExecutive Change · Results of OperationsJan 8, 20248-KExecutive Change · Bylaw AmendmentDec 20, 202310-Q10-QNov 1, 20238-KResults of OperationsNov 1, 20238-KExecutive ChangeSep 19, 20238-KExecutive ChangeAug 23, 202310-Q10-QAug 1, 20238-KResults of OperationsAug 1, 20238-KCompany UpdateJul 24, 20238-KShareholder VoteJun 5, 2023DEFA14ADEFA14AMay 17, 2023DEFA14ADEFA14AMay 15, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AMay 8, 20238-KExecutive Change · Company UpdateMay 8, 2023DEFA14ADEFINITIVE ADDITIONAL MATERIALSMay 2, 2023DEFA14ADEFA14AMay 1, 2023DEFA14ADEFA14AApr 13, 20238-KExecutive Change · Company UpdateApr 13, 2023DEFA14ADEFA14AApr 6, 20238-KCompany UpdateMar 22, 2023SC 13DEXELIXIS, INC.Mar 20, 2023SC 13DSC 13DMar 20, 20238-KCompany UpdateMar 20, 202310-K10-KFeb 7, 20238-KResults of OperationsFeb 7, 20238-KResults of OperationsJan 9, 20238-KExecutive ChangeDec 15, 202210-Q10-QNov 1, 20228-KResults of OperationsNov 1, 20228-KCompany UpdateSep 2, 202210-Q10-QAug 9, 20228-KResults of OperationsAug 9, 20228-KCompany UpdateJul 19, 20228-KExecutive Change · Shareholder VoteMay 27, 202210-Q10-QMay 10, 2022
Insider Activity
In the 90 days to Feb 24, 2026: 8 sold $20.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 | Aftab DanaEVP, Research and Development | Sell | 47,918 | $44.50 | $2.1M |
| Feb 19, 2026 | Aftab DanaEVP, Research and Development | Sell | 29,873 | $44.35 | $1.3M |
| Feb 18, 2026 | Wyszomierski Jack LDirector | Sell | 99,574 | $44.01 | $4.4M |
| Feb 18, 2026 | Smith JulieDirector | Sell | 44,087 | $44.50 | $2.0M |
| Feb 18, 2026 | Smith JulieDirector | Sell | 20,030 | $44.30 | $887K |
| Feb 18, 2026 | Hefti BrendaSVP and General Counsel | Sell | 18,669 | $44.01 | $822K |
| Feb 17, 2026 | Haley Patrick J.EVP, Commercial | Sell | 64,778 | $43.50 | $2.8M |
| Feb 17, 2026 | Smith JulieDirector | Sell | 42,422 | $43.33 | $1.8M |
| Feb 17, 2026 | Senner Christopher J.EVP and CFO | Sell | 30,617 | $43.67 | $1.3M |
| Feb 17, 2026 | Haley Patrick J.EVP, Commercial | Sell | 3,036 | $43.84 | $133K |
| Feb 13, 2026 | Senner Christopher J.EVP and CFO | Sell | 34,278 | $43.00 | $1.5M |
| Feb 13, 2026 | Oliver BobDirector | Sell | 21,162 | $43.90 | $929K |
| Feb 13, 2026 | Oliver BobDirector | Sell | 9,088 | $43.61 | $396K |
| Feb 13, 2026 | Eckhardt Sue GailDirector | Sell | 3,856 | $43.79 | $169K |
| Nov 25, 2025 | Caligan Partners LpDirector,Other | Buy | 27,532 | $43.12 | $1.2M |
| Nov 21, 2025 | Haley Patrick J.EVP, Commercial | Sell | 28,043 | $42.58 | $1.2M |
| Nov 20, 2025 | Haley Patrick J.EVP, Commercial | Sell | 23,539 | $41.93 | $987K |
| Nov 20, 2025 | Haley Patrick J.EVP, Commercial | Sell | 10,648 | $41.77 | $445K |
| Nov 20, 2025 | Haley Patrick J.EVP, Commercial | Sell | 10,000 | $42.11 | $421K |
| Nov 12, 2025 | Papadopoulos SteliosDirector | Sell | 100,000 | $43.55 | $4.4M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance